Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
Mechelen, Belgium; 21 February 2014 - Galapagos NV (Euronext: GLPG) announced
today that the Company will present posters on GLPG0634 and GLPG0974 at the
European Crohn's and Colitis Organisation annual meeting, taking place from 20
to 22 February 2014 in Copenhagen, Denmark. The full abstracts can be accessed
through the ECCO website.
GLPG0634, The First Selective JAK1 Inhibitor, Shows Strong Activity In The Mouse
DSS-Colitis Model
Abstract number: A-1737
Poster number: P072
GLPG0634 is an orally-available, novel JAK inhibitor with selectivity for JAK1,
developed by Galapagos. Â JAKs are critical components of signalling mechanisms
utilized by a number of cytokines and growth factors, including those that are
elevated in Crohn's patients. The strong efficacy of GLPG0634 in the pre-
clinical mouse DSS-induced colitis model will be presented during a poster
session on Friday, February 21, 2014, from 12:20-13:30. The poster is available
online at www.glpg.com.
The FFA2 antagonist GLPG0974: opportunity to treat neutrophil-driven
inflammation
Abstract Number: A-1557
Poster number: DOP070
FFA2 (free fatty acid receptor 2) has been shown to play a role in neutrophil
migration. Â Over-activity of neutrophils is a cause of tissue damage in
illnesses such as inflammatory bowel disease. The favorable Phase 1
pharmacokinetic, pharmacodynamic, and safety data with GLPG0974 will be
presented on Friday, February 21, 2014, from 12:25-13:25 in DOP Session Room 8
in Hall B. The presentation is available online at www.glpg.com.
About candidate drug GLPG0634
GLPG0634 differentiates from other JAK inhibitors in development by specifically
targeting JAK1, a strategy which could result in a better efficacy and safety
profile. GLPG0634 is a fully proprietary program.  Upon successful completion
of the Phase 2b studies in RA, AbbVie will license the program and will assume
sole responsibility for Phase 3 clinical development and global manufacturing.
 Furthermore, Galapagos recently announced the start of a Phase 2 study with
GLPG0634 in Crohn's Disease.
About candidate drug GLPG0974
GLPG0974 is an orally available small molecule that reduces migration of
neutrophils, one of the critical cell types in inflammatory processes, by potent
inhibition of FFA2 (also known as GPR43). Â Over-activity of neutrophils is a
cause of tissue damage in illnesses such as inflammatory bowel disease. Â A
reduction of neutrophil activation and migration by inhibition of FFA2 may
provide for a novel anti-inflammatory treatment approach. Â By inhibiting FFA2,
GLPG0974 prevents free fatty acid-induced activation and migration of
neutrophils towards an inflammatory site, such as in the gut of patients with
inflammatory bowel disease. Â GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically.
About ECCO
The European Crohn's and Colitis Organisation (ECCO), founded in 2001, is now
the largest forum for specialists in IBD in the world. Â It is a non-profit
association, which successfully expanded from an organisation comprising 14
Country Members to an association assembling 33 member states of the Council of
Europe and facilitating collaborations beyond Europe's borders. ECCO's mission
is to improve the care of patients with IBD in all its aspects through
international guidelines for practice, education, research and collaboration in
the area of IBD. Â More info at: https://www.ecco-ibd.eu/
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising of six Phase 2 studies (three led by GSK), one
Phase 1 study, six pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and
other indications. In the field of inflammation, AbbVie and Galapagos signed a
worldwide license agreement whereby AbbVie will be responsible for further
development and commercialization of GLPG0634 after Phase 2B. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. Galapagos has another
selective JAK1 inhibitor in Phase 2 in ulcerative colitis, psoriasis, and lupus,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).
GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the
treatment of IBD; this program is currently in a Proof-of-Concept Phase 2
study. GLPG1205 is a first-in-class molecule that targets inflammatory
disorders and has completed Phase 1. Â AbbVie and Galapagos signed an agreement
in CF where they work collaboratively to develop and commercialize oral drugs
that address two mutations in the CFTR gene, the G551D and F508del mutation.
Potentiator GLPG1837 is at the pre-clinical candidate stage. The Galapagos
Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has
around 800 employees and operates facilities in five countries, with global
headquarters in Mechelen, Belgium. Further information at: www.glpg.com
Contact
Elizabeth Goodwin, Head of Corporate Communications & Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos to present GLPG0634 and GLPG0974 at ECCO:
http://hugin.info/133350/R/1763510/597669.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1763510]